Spero Therapeutics (SPRO) Operating Expenses (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Operating Expenses came in at $7.8 million in Q1 2026, down 62.16% YoY from $20.6 million in Q1 2025, and down 21.19% on a QoQ basis from $9.9 million in Q4 2025.
Spero Therapeutics (SPRO) Operating Expenses (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Operating Expenses data on file, last reported at $7.8 million in Q1 2026.
- Quarterly Operating Expenses fell 62.16% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.7 million (down 59.83% YoY) and the FY2025 annual result came in at $60.5 million, down 50.15% from the prior year.
- Operating Expenses slipped to $7.8 million in Q1 2026, from $9.9 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $36.8 million in Q4 2024 to a low of $7.8 million in Q1 2026.
- A 5-year average of $21.6 million and a median of $21.5 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses surged 98.03% — and 2025, when it sank 73.1%.
- Tracing SPRO's Operating Expenses over 5 years: stood at $21.5 million in 2022, then gained by 6.85% to $23.0 million in 2023, then soared by 59.93% to $36.8 million in 2024, then slumped by 73.1% to $9.9 million in 2025, then fell by 21.19% to $7.8 million in 2026.
- The last three Operating Expenses figures came in at $7.8 million (Q1 2026), $9.9 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 9.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.93 Mn |
| Mar 31, 2026 | 7.80 Mn |
| Dec 31, 2025 | 9.89 Mn |
| Sep 30, 2025 | 13.36 Mn |
| Jun 30, 2025 | 16.63 Mn |
| Mar 31, 2025 | 20.61 Mn |
| Dec 31, 2024 | 36.77 Mn |
| Sep 30, 2024 | 32.06 Mn |
| Jun 30, 2024 | 29.26 Mn |
| Mar 31, 2024 | 23.25 Mn |
| Dec 31, 2023 | 22.99 Mn |
| Sep 30, 2023 | 27.41 Mn |
| Jun 30, 2023 | 15.61 Mn |
| Mar 31, 2023 | 16.30 Mn |
| Dec 31, 2022 | 21.52 Mn |
| Sep 30, 2022 | 13.84 Mn |
| Jun 30, 2022 | 28.07 Mn |
| Mar 31, 2022 | 32.28 Mn |
| Dec 31, 2021 | 30.25 Mn |
| Sep 30, 2021 | 25.59 Mn |